The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

ABSTRACT: Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas^1-3. More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours⁴. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer⁵, there are preclinical^6-19 and clinical^20,21 rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the

SUBMITTER: Janjigian YY 

PROVIDER: S-EPMC8959470 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature